TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02216253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract
Description: L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract tablet twice a day 7 days before and after surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet twice a day 7 days before and after surgery
Study: NCT00316303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Twinrix
Description: This vaccine will be given in three parts: at entry and after 3 and 6 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced treatment as usual
Description: Participants will receive comprehensive mental health services provided at each study site, education about blood-borne diseases, and referral to a local community health provider for blood testing, HAV and HBV immunizations, and any necessary treatments.
Study: NCT01434472

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO
Study: NCT02992613

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total knee arthroplasty with ultra-congruent (UC) insert
Study: NCT05820373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga therapy
Description: Women being allocated to the intervention group will attend a 12-week, bi-weekly, specially designed yoga therapy course. In each yoga class, participants will be taught to perform a standardized yoga sequence including postures and breathing exercise. Each class lasts 60 minutes. A DVD demonstrating the yoga sequence will be given to each participant to prompt daily home practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control group
Description: Women being allocated to the active control group will attend a 12-week, weekly, relaxation course. In each relaxation class, participants will be taught to learn mediation and guided relaxation, called Shavasana. Participants will be asked to lie on their back, with legs apart and their eyes closed. During the practice, participants learn how to relax the body and breath normally. Each session lasts 60 minutes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Passive control group
Description: The passtive control intervention will be the standard post-operative exercises which are currently introduced to women following surgery, for all women allocated to the control group. A DVD demonstrating the post-operative exercise will be given to participants to practice at home daily.
Study: NCT03530527

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP with biliary stenting
Description: ERCP with biliary stent is performed using a side view duodenoscope of Olympus (TJF-160). Biliary cannulation is performed using a sphincterotome and 0.035 inch jag wire, and cholangiogarm is done to assess common bile duct diameter, and length of biliary stricture. Biliary sphincterotomy is then performed. A straight biliary stent is placed across stricture bile duct.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS guided biliary drainage
Description: EUS guided biliary drainage is performed using a linear echoendoscope of Olympus (GFUCT240). Extrahepatic bile duct was identified from duodenal bulb, then 19 G needle is inserted into bile duct with confirmed with cholangiogram. The fistula tract is dilated using a 6 Fr cystotome (Wilson Cook Medical). A double pigtail stent is placed across biliary-enteric fistula.
Study: NCT02740439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avocado
Description: The intervention meals will contain 1 large avocado.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control meals will be isocaloric to the intervention meals but will not contain avocado.
Study: NCT00933829

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable Suture Arm
Description: use of irradiated polyglactin 910

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-absorbable suture (Prolene)
Description: suture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suture
Description: non-absorable sutures and absorable sutures

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: suture
Description: non-absorable sutures and absorable sutures
Study: NCT01395667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CCRT
Description: Combined IMRT with three escalated dose levels (45 Gy, 50 Gy, and 55 Gy in 25 fractions) and Bevacizumab-fluorouracil/ leucovorin/oxaliplatin (FOLFOX) regimens
Study: NCT04351854

Intervention type: OTHER
Intervention: Retrospective data collection
Description: Retrospective data collection to identify predicting factors in the clinical picture of COVID-19 patients presenting to the ED.
Study: NCT04043767

Intervention type: PROCEDURE
Intervention: Measurements of thyromental distances, hyomental distances and neck circumferences
Description: thyromental distances, hyomental distances and neck circumferences using measurement tape by two independent investigators.
Study: NCT02772315

Intervention type: OTHER
Intervention: omics
Description: diagnostic procedures applying omics results
Study: NCT00646451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin (Lyrica)
Description: 75 mg bid to 300 mg bid based on per subject tolerability

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: up to 4 capsules bid as tolerated
Study: NCT01510912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: 35 mg bid or tid Capsules
Study: NCT03745118

Intervention type: DEVICE
Group type: OTHER
Intervention: EpiTel EpiLog
Description: Plastic pad that is about the size of a house key, and will be adhered to your scalp with gel
Study: NCT01434472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Indium In-111 Ibritumomab Tiuxetan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV prior to yttrium Y 90 ibritumomab tiuxetan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y-90 Ibritumomab Tiuxetan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study: NCT01401816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Subjects will receive a text message on their personal cell phone on Days 1, 3 and 5 after enrollment reminding them to fill their prescription.
Study: NCT04567966

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Split-block technique
Description: Horizontal ridge augmentation using the split-block technique where a cortical bone plate harvested from the external oblique ridge was split in half and fixed at a distance from the atrophied ridge. Then autogenous bone chips were packed in the gap between the plate and the ridge.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cortico-cancellous block graft
Description: Horizontal ridge augmentation using a cortico-cancellous block harvested from the chin of the mandible.
Study: NCT01240044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracoabdominal rebalancing
Description: In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: In this group the newborns were first submitted to the mechanical vibrator applied over a diaper, on the chest of newborns for 5 min, as follows: 1min 1min right hemithorax and the left hemithorax, both previously, followed 30 seconds in the lateral aspect of each hemithorax; more than 1min in each hemithorax in the posterior region. The mechanical vibrator was performed subsequent to manual chest compression, using light hand pressure on the chest of newborns, respecting the compliance of the chest. The chest compression was applied for 2min 2min in the right hemithorax and left-sided chest, above, and 1 minute on each side, another 2 minutes on the back of each hemithorax, totaling 10 minutes of compression. Next to chest compression, mechanical vibration was applied for 5 min in the same topographical sequence described.
Study: NCT02992613

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty with posterior-stabilized (PS) insert
Study: NCT01530308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: An oral dosage of 1mg twice daily at 12am and 8pm.
Study: NCT02002442

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwash
Description: An investigator will give the patient the assigned mouthwash based on the randomized group allocation. 30ml of the mouthwash will be given to the subject in a sterilized calibrated tube. The subject will be asked to rinse for 60 seconds. Then, the patient will spit the mouthwash.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwash
Description: An investigator will give the patient the assigned mouthwash based on the randomized group allocation. 30ml of the mouthwash will be given to the subject in a sterilized calibrated tube. The subject will be asked to rinse for 60 seconds. Then, the patient will spit the mouthwash.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwash
Description: An investigator will give the patient the assigned mouthwash based on the randomized group allocation. 30ml of the mouthwash will be given to the subject in a sterilized calibrated tube. The subject will be asked to rinse for 60 seconds. Then, the patient will spit the mouthwash.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mouthwash
Description: An investigator will give the patient the assigned mouthwash based on the randomized group allocation. 30ml of the mouthwash will be given to the subject in a sterilized calibrated tube. The subject will be asked to rinse for 60 seconds. Then, the patient will spit the mouthwash.
Study: NCT02656992

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inspiratory muscle training group

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training group
Study: NCT01530308

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An oral dosage of 1mg twice-daily at 12am and 8 pm.
Study: NCT04661488

Intervention type: DEVICE
Intervention: AI driven triage-system
Description: AI driven triage-system
Study: NCT02918331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab (16 mg/kg)
Description: Daratumumab (16 mg/kg) will be administered by IV infusion to all participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity or study end.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Participants will receive lenalidomide 25 mg orally on Days 1 through 21 of each 28 day cycle. Participants with creatinine clearance (CrCl) between 30 and 60 milliLitre (mL)/minute (min) will receive lenalidomide 10 mg every 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will receive dexamethasone 40 mg weekly, at day 1, 8, 15, 22 of each cycle.
Study: NCT03398018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repository corticotropin injection
Description: 80 units twice per week as a subcutaneous injection
Study: NCT02256332

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low dose plant based ingredient
Description: Reference food with low dose of plant based ingredient
Study: NCT00263731

Intervention type: OTHER
Intervention: 13-C-glucose
Description: 10 grams of 13-C-glucose intravenously, as a 30-minute piggyback infusion, 2 to 6 hours prior to scheduled surgical resection of primary lung cancer.
Study: NCT03146377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1250 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 IV on day 1 of a 2-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 165 mg/m2 IV on day 1 of a 2-week cycle
Study: NCT01199172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: voice hygiene
Description: subjects will receive voice hygiene training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VH + VP
Description: subjects will be trained in voice hygiene and voice production training
Study: NCT02549534

Intervention type: PROCEDURE
Intervention: Axon Reflexes
Description: \*Axon reflexes will be evoked in the palmar surface of the right great toe using local skin heating with a 0.33 cm2 heat probe using the following protocol:~* Baseline: Heating the skin of the toe for a minimum of 5 minutes at 33\*C.~* Heat Ramp: Increasing the heat in the heat probe to 42\*C at approx. 0.1\*C/10 sec.~* Skin Heating: Heating the skin of the toe for 30 minutes 42\*C.~* Heat Ramp: Increasing the heat in the heat probe to 44\*C at 0.1\*C/10 sec..~* Skin Heating: Heating the skin for an additional 5 minutes at 44\*C.~The size of the axon reflex during this skin heating protocol will be imaged using Laser Doppler Flowmetry (LDF). In the case that participants develop CIPN on their left side only, the left toe will be substituted.

Intervention type: PROCEDURE
Intervention: Axon Reflexes
Description: \*Axon reflexes will be evoked in the palmar surface of the right great toe using local skin heating with a 0.33 cm2 heat probe using the following protocol:~* Baseline: Heating the skin of the toe for a minimum of 5 minutes at 33\*C.~* Heat Ramp: Increasing the heat in the heat probe to 42\*C at approx. 0.1\*C/10 sec.~* Skin Heating: Heating the skin of the toe for 30 minutes 42\*C.~* Heat Ramp: Increasing the heat in the heat probe to 44\*C at 0.1\*C/10 sec..~* Skin Heating: Heating the skin for an additional 5 minutes at 44\*C.~The size of the axon reflex during this skin heating protocol will be imaged using Laser Doppler Flowmetry (LDF). In the case that participants develop CIPN on their left side only, the left toe will be substituted.

Intervention type: PROCEDURE
Intervention: Axon Flares
Description: Axon flares will be generated on the palmar surface of the right great toe using the same local skin heating protocol described above, and imaged using a laser speckle contrast imager (LSCI) (also known as full-field laser perfusion imager, or FLPI).

Intervention type: PROCEDURE
Intervention: Axon Flares
Description: Axon flares will be generated on the palmar surface of the right great toe using the same local skin heating protocol described above, and imaged using a laser speckle contrast imager (LSCI) (also known as full-field laser perfusion imager, or FLPI).
Study: NCT03745118

Intervention type: DEVICE
Group type: OTHER
Intervention: Byte Flies Sensor Dots
Description: Plastic pads that will be adhered to your chest area

Intervention type: DEVICE
Group type: OTHER
Intervention: Empatica E4
Description: wearable seizure detection wristband

Intervention type: DEVICE
Group type: OTHER
Intervention: Biovotion Everion
Description: wearable seizure detection device armband that is attached to upper arm

Intervention type: DEVICE
Group type: OTHER
Intervention: GeneActiv
Description: wearable seizure detection watch
Study: NCT02549534

Intervention type: PROCEDURE
Intervention: Self-Reported Signs & Symptoms of CIPN
Description: Self-reported signs \& symptoms of CIPN such as the presence and location of (1) tingling, (2) numbness, and (3) neuropathic pain, along with information about (4) deficits in vibration thresholds, and (5) loss of deep tendon reflexes will be assessed at each study visit using the 5-item, modified Total Neuropathy Score (mTNS).

Intervention type: PROCEDURE
Intervention: Self-Reported Signs & Symptoms of CIPN
Description: Self-reported signs \& symptoms of CIPN such as the presence and location of (1) tingling, (2) numbness, and (3) neuropathic pain, along with information about (4) deficits in vibration thresholds, and (5) loss of deep tendon reflexes will be assessed at each study visit using the 5-item, modified Total Neuropathy Score (mTNS).
Study: NCT03376269

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HBOT
Description: •HBOT of 2 ATA for 90 minutes O2 100%, for 60 treatments

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: creative art psychotherapy which includes self drawing and daily diary alongside professional psychotherapy sessions

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychotherapy
Description: creative art psychotherapy which includes self drawing and daily diary alongside professional psychotherapy sessions
Study: NCT03463512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racecadotril plus ORS
Description: Racecadotril plus ORS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORS
Description: ORS
Study: NCT01627483

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Medication review
Description: Assessment of risks of falls and fractures; medication review concerning fall-risk-increasing and fracture-preventing drugs; oral and written feed back of the results of the assessments and medication reviews to the hospital physician during the hospital stay and to the general practitioner 3 and 6 months after the hip fracture surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication review
Description: Assessment of risks of falls and fractures; medication review concerning fall-risk-increasing and fracture-preventing drugs; oral and written feed back of the results of the assessments and medication reviews to the hospital physician during the hospital stay and to the general practitioner 3 and 6 months after the hip fracture surgery.
Study: NCT02931656

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aquatic exercise
Description: The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Description: The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
Study: NCT03872297

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Consumption of a non active food complement during 3 months.~Tests performed :~* 2 blood tests :~* 2 body composition analysis via Dual-energy X-ray absorptiometry (DXA)~* 2 stool collections The first one of these analysis was performed at the beginning, second at the end of the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Naticol supplement
Description: Consumption of the active food complement during 3 months containing Naticol.~Tests performed :~* 2 blood tests :~* 2 body composition analysis via Dual-energy X-ray absorptiometry (DXA)~* 2 stool collections The first one of these analysis was performed at the beginning, second at the end of the study.
Study: NCT04404062

Intervention type: DIAGNOSTIC_TEST
Intervention: Membrane-based immunoassay kit
Description: The kit is a qualitative membrane-based immunoassay to detect IgG and IgM antibodies to SARS-CoV-2 in whole blood, serum or plasma specimens. IgG and IgM detection components are separate allowing for differential detection of each antibody.

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative antibody Tests
Description: Antibody titres will be measured from whole blood samples taken from volunteers.

Intervention type: DIAGNOSTIC_TEST
Intervention: PCR Test
Description: PCR tests will be conducted on throat swabs taken from volunteers.
Study: NCT04641858

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG-Denmark
Description: Participants randomized to receive BCG will receive one 0.1 ml dose of Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) by intradermal injection in the left deltoid region.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the right deltoid region.
Study: NCT04032548

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthwash
Description: After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).